Navigation Links
BU team wins $4.1M genome grant
Date:9/15/2010

BOSTON (9-15-10) -- A team led by Boston University biomedical engineering researchers has won a $4.1 million, four-year grant from the National Institutes of Health to refine its nanoscale, low-cost, ultra-fast DNA sequencing method that could lead to individual genome sequencing for less than $1,000.

Developed in the past four years on an initial, $2.2 million NIH grant and led by Boston University Biomedical Engineering Professor Amit Meller, the project is one of 10 to receive funding from the NIH National Human Genome Research Institute (NHGRI) this year under its "Revolutionary Sequencing Technology Development$1,000 Genome" program. The new NHGRI awards were announced this week.

Since its founding in 2004, the $1,000 Genome program has produced innovations that have reduced the cost of genome sequencing from $10 million to $20,000, and cut the time needed to complete the process from a few months to a week. But reaching the $1,000 mark will require creative, unprecedented approaches.

Toward that end, Meller and his team have already demonstrated the first use of solid state nanoporesfour-nanometer-wide holes in silicon chips that read DNA strands as they pass throughto optically sequence the four nucleotides that encode each DNA molecule. Their novel, highly efficient, optically-based method to detect single DNA molecules in nanopores could significantly reduce the cost of DNA sequencing and the time required to sequence a complete human genome.

"We are the first to employ optical detection from individual nanopores, and this allows us to probe multiple pores simultaneously using a single high-speed CCD camera," said Meller, referring to the charge-coupled devices that researchers use to obtain high-quality images. "As a result, our method can be scaled up vastly, ultimately allowing us to probe thousands of nanopores and obtain unprecedented DNA sequencing throughput."

Combining optical detection capability with the ability to analyze extremely long DNA molecules with superior sensitivity, the team's solid state nanopores are uniquely positioned to compete with current, third-generation DNA sequencing methods for cost, speed and accuracy. Unlike those approaches, the new nanopore method does not rely on enzymes whose activity limits the rate at which DNA sequences can be read; instead, readout speed is restricted only by current optical detection limits.

"This puts us in the unique advantageous position of being able to claim that our sequencing method is as fast as the rapidly evolving CCD/CMOS technologies," said Meller. "We currently have the capability of reading out about 100 bases per second, which is already much faster than other commercial third generation methods. This is only the starting point for us, and we expect to significantly increase this rate in the next year."

Licensing intellectual property from Boston University and Harvard University, Meller and his collaborators founded NobleGen Biosciences last February to develop and commercialize nanopore sequencing based on the new method. Researchers from the University of Massachusetts Medical School in Worcester are also working on the current project.

"Given the aggressive research and development effort that's now underway, I estimate that it will take less than five years to bring a highly competitive and cheap DNA sequencing to the medical marketplace" said Meller.


'/>"/>

Contact: Mike Seele
mseele@bu.edu
617-353-9766
Boston University College of Engineering
Source:Eurekalert  

Related biology news :

1. NC State researchers get to root of parasite genome
2. Worm genome offers clues to evolution of parasitism
3. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
4. Diatom genome helps explain success in trapping excess carbon in oceans
5. Washington University scientists first to sequence genome of cancer patient
6. Research consortium to sequence turkey genome
7. DOE Joint Genome Institute completes soybean genome
8. Breast cancer genome shows evolution, instability of cancer
9. In lung cancer, silencing one crucial gene disrupts normal functioning of genome
10. Gene switch sites found mainly on shores, not just islands of the human genome
11. Genome Medicine: Bridging the gap between research and clinical practice
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BU team wins $4.1M genome grant
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... 28, 2017 Sangamo Therapeutics, Inc. (NASDAQ: ... reported its fourth quarter and full year 2016 ... this year we rebranded our company as Sangamo ... genomic therapies using our industry leading platform technologies ... cell therapy," said Sandy Macrae , CEO ...
(Date:2/28/2017)... , February 28, 2017 The ... for assessment are the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ... AUPH ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... companies belong to the Healthcare sector, which was narrowly mixed ... Health Care Index declining less than 0.1%, while shares of ...
(Date:2/27/2017)... , February 27, 2017 A Europe-wide ... indicated that researchers using animals in their research treat them with ... 26 countries, and detailed analysis of the results indicates that there ... to put into practice the principles of the 3Rs ... ...
(Date:2/27/2017)... CITY, Calif. , Feb. 27, 2017 /PRNewswire/ ... pharmaceutical company focused on the development and commercialization ... acute pain, announced today the U.S. Food and ... Drug Application (NDA) under section 505(b)(2) for DSUVIA™ ... the treatment of patients with moderate-to-severe acute pain ...
Breaking Biology Technology: